Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Quantum Biopharma ( (TSE:QNTM) ) has issued an update.
On June 13, 2025, Quantum BioPharma announced its intention to declare a special dividend of Contingent Value Rights (CVRs) to its Class B Subordinate Voting Shareholders. These CVRs are linked to potential proceeds from a legal action against several banks for alleged stock price manipulation. The CVRs, which will not be listed or transferable, offer shareholders a pro rata share of 10% to 50% of any net proceeds recovered. This move underscores the company’s commitment to aligning shareholder interests with the outcome of the litigation, though the issuance is subject to regulatory approvals and other conditions.
More about Quantum Biopharma
Quantum BioPharma Ltd. is a biopharmaceutical company focused on developing innovative assets and biotech solutions for treating neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. The company is engaged in the research and development of its lead compound, Lucid-MS, aimed at preventing and reversing myelin degradation in multiple sclerosis. Quantum BioPharma also maintains strategic investments through its subsidiary, FSD Strategic Investments Inc., and holds a stake in Unbuzzd Wellness Inc., which markets an OTC product for alcohol misuse.
Average Trading Volume: 8,897
Technical Sentiment Signal: Sell
Current Market Cap: C$61.06M
See more insights into QNTM stock on TipRanks’ Stock Analysis page.